Navigation Links
Accelr8 Announces Results of 2012 Annual Meeting

DENVER, Dec. 13, 2012 /PRNewswire/ -- Accelr8 Technology Corporation (NYSE MKT: AXK) announced today the results of its 2012 Annual Meeting of Shareholders, which was held on Wednesday, December 12, 2012.  At the Annual Meeting, shareholders re-elected Lawrence Mehren, John Patience, Jack Schuler and Matthew Strobeck, Ph.D. as directors of the Company.  Proposals to reincorporate the Company in Delaware, change the Company's name to "Accelerate Diagnostics, Inc.", approve a new Certificate of Incorporation, approve a new Omnibus Equity Incentive Plan, and ratify the selection of Comiskey & Company, P.C. as the Company's independent auditors for the upcoming fiscal year were also approved by shareholders.

The Company plans to file documents with the Delaware and Colorado Secretaries of State to complete the reincorporation in Delaware and the name change described above as soon as possible. 

For more information about the proposals that were approved by the Company's shareholders at the Annual Meeting, refer to the Definitive Proxy Statement that the Company filed with the Securities and Exchange Commission on November 13, 2012, which is available at

About Accelr8
Accelr8 Technology Corporation is focused on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens.  The Company's BACcel™ platform utilizes a proprietary culture-free process with both genomic and phenotypic detection technologies that decrease time to result while maintaining high sensitivity and specificity. 

Disclaimer Regarding Forward-Looking Statements
Certain statements in this news release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the Company's filings with the SEC.  The Company does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.

SOURCE Accelr8 Technology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelr8 to Hold 2012 Annual Meeting of Shareholders; Product Development Continues with Launch Expected in 2015
2. Accelr8 Appoints Steve Reichling Chief Financial Officer
3. OncoSec Medical Announces $7.2 Million Public Offering
4. Isis Announces That ISIS-TTR Rx Was Granted Fast Track Designation For The Treatment Of Patients With FAP
5. MAQUET Cardiovascular Announces U.S. Food and Drug Administration Panel Votes To Reclassify Intra-Aortic Balloon Pumps To A Class II Designation In Certain Indications
6. CVS Caremark Provides Strong Growth Outlook for 2013 and Beyond, Announces 38%Dividend Increase and Outlines Strategic Growth Framework
7. AstraZeneca Announces Top-Line Results of OSKIRA-4 Phase IIb Study of Fostamatinib as a Monotherapy for Rheumatoid Arthritis
8. Mylan Announces Pricing of Senior Notes
9. AAIPharma Announces Promotion Of Dean Shirazi To EVP Of Analytical Laboratories
10. Alere Inc. Announces Hiring of Namal Nawana as Chief Operating Officer
11. Northwest Biotherapeutics, Inc. Announces Full Exercise of Over- Allotment Option
Post Your Comments:
(Date:11/27/2015)... , Pays-Bas, November 27, 2015 ... l,immunothérapie au traitement photodynamique au Bremachlorin contre le ... nouvelle approche consistant à combiner l,immunothérapie au traitement ...    --> Une nouvelle approche ... Bremachlorin contre le cancer avancé.    ...
(Date:11/27/2015)... 2015 --> ... online. The potential to save costs, improve treatment quality ... from fully exploited as yet. Here, particular emphasis is ... via mobile tablet or directly at the patients, bedside. ... ) -->      (Photo: ...
(Date:11/27/2015)... November 27, 2015 Ein ... fortgeschrittenem Krebs.   --> Ein neuer ... Krebs.   --> Ein neuer ... Krebs.   Clinical Cancer Research ... Clinical Cancer Research vom 6. November 2015 ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... The moment you stop ... not only fulfilling the needs of advisers and clients but going above and ... providing top-tier customer service. However, there's always room for improvement, which is why ...
(Date:11/27/2015)... ... 2015 , ... The men and women on this list ... the country. They have overseen financial turnarounds, shown commitment to their community through ... as a whole through their advocacy and professional efforts. , Becker's Hospital Review ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., developer and ... of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. ... 5.10 up-to-date with a version of Asterisk that will receive not only security ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge ... imaging in the Waterloo region. Using the Ocean Platform, family physicians can now ... their electronic medical record (EMR) without the need for redundant patient entry or ...
(Date:11/26/2015)... ... ... Jobs in hospital medical laboratories and in the imaging field lead the ... Aureus Medical Group . These fields, as well as travel nursing, ranked ... jobs through the company’s website, , The leading healthcare staffing agency ...
Breaking Medicine News(10 mins):